Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.57 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.57 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.57 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.57 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.57 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.57 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.57 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.57 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CPN1 | P15169 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL856745 | 1.00 | SLC6A1 (0.57) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL2832801 | 1.00 | SLC6A1 (0.57) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| Hydrochloric Acid SCHEMBL15662845 | 0.98 | SLC6A1 (0.55) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| Bromide SCHEMBL23881409 | 0.98 | SLC6A1 (0.55) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| Hydrochloric Acid SCHEMBL3830642 | 0.98 | SLC6A1 (0.55) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL2768724 | 0.89 | CYP2D6 (0.51) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL5649078 | 0.89 | CYP2D6 (0.51) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL477374 | 0.89 | CYP2D6 (0.51) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL477247 | 0.88 | ALOX15 (0.58) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| Hydrochloric Acid SCHEMBL4014842 | 0.87 | CYP2D6 (0.50) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119528903-A | Compounds for the treatment of spinal muscular atrophy | PTC医疗公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-113950477-B | Granulin precursor modulators and methods of use thereof | 阿库达医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-117412964-A | Substituted heterocyclic compounds and their use | 首药控股(北京)股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| US-10683307-B2 | Compounds for use in antibacterial applications | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-06-16 | — | — | US | disclosed |
| US-20190270755-A1 | COMPOUNDS FOR USE IN ANTIBACTERIAL APPLICATIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-09-05 | — | — | US | disclosed |
| US-10364254-B2 | Compounds for use in antibacterial applications | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
| US-20190031680-A1 | COMPOUNDS FOR US IN ANTIBACTERIAL APPLICATIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-31 | — | — | US | disclosed |
| EP-3334739-A2 | ANTIBACTERIAL AGENTS COMPRISING A PYRAZINO[2,3-B][1,4]OXAZIN-3-ONE OR A RELATED RING SYSTEM | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-06-20 | — | — | EP | disclosed |
| WO-2017029602-A2 | COMPOUNDS FOR USE IN ANTIBACTERIAL APPLICATIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-02-23 | — | — | WO | disclosed |
| EP-2044077-B1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LTD (GB) | 2016-10-05 | — | — | EP | disclosed |
| EP-1796466-A4 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2009-09-02 | — | — | EP | disclosed |
| EP-1784393-B1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-2044077-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | Glaxo Group Limited (GB) | 2009-04-08 | — | — | EP | disclosed |
| EP-1992628-A1 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2008-11-19 | — | — | EP | disclosed |
| WO-2008009700-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | WO | disclosed |
| EP-1796466-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-06-20 | — | — | EP | disclosed |
| EP-1784393-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006028904-A9 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006028904-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006002047-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683307-B2 | Compounds for use in antibacterial applications | MRPL21, CFTR, NRDC | SLC6A1 1848/4885GABRA5 3968/4885GABRB2 3684/4885 |
| US-20190270755-A1 | COMPOUNDS FOR USE IN ANTIBACTERIAL APPLICATIONS | MRPL21, CFTR, NRDC | SLC6A1 1848/4885GABRA5 3968/4885GABRB2 3684/4885 |
| US-20190031680-A1 | COMPOUNDS FOR US IN ANTIBACTERIAL APPLICATIONS | CFTR, MRPL21, CLPP | SLC6A1 2808/4885GABRA5 4330/4885GABRB2 4083/4885 |
| US-10364254-B2 | Compounds for use in antibacterial applications | MRPL21, CFTR, NRDC | SLC6A1 1848/4885GABRA5 3968/4885GABRB2 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.